Skip to content

Hepatocellular carcinoma in MASH/MASLD

TL;DR — MASLD-related HCC is a population-scale paradox: individual annual risk is low without cirrhosis, yet MASLD is so prevalent that it is the fastest-growing HCC cause in several Western countries (Huang 2021, PMID 33349658). Estimated HCC incidence is 0.5%–2.6% per year in MASH/NASH cirrhosis but only ~0.1–1.3 per 1,000 patient-years in non-cirrhotic NAFLD, making blanket non-cirrhotic surveillance untenable (Huang 2021, PMID 33349658). A Korean national cohort still found non-cirrhotic NAFLD associated with HCC (adjusted HR 2.69, 95% CI 1.33–5.44), showing that low absolute risk and elevated relative risk can coexist (Lee 2025, PMID 40345323). Obesity can degrade ultrasound, and disease can arise before cirrhosis is recognized, jointly creating an early-detection gap. Preclinical and retrospective work raised concern that NASH biology may attenuate checkpoint benefit, but this is not a validated clinical reason to withhold immunotherapy (Pfister 2021, PMID 33762733).

Terminology and evidence continuity

Most evidence was generated under NAFLD/NASH terminology. MASLD/MASH introduces affirmative cardiometabolic criteria and changes alcohol-related category boundaries. This improves etiologic framing but complicates historical comparison.

Current term Historical evidence term Practical issue
MASLD NAFLD Cohorts are not perfectly interchangeable
MASH NASH Histologic and non-invasive definitions vary
MetALD NAFLD plus moderate alcohol often excluded Mixed exposure becomes explicit
Cryptogenic cirrhosis Burnt-out NASH in some cases Etiology may be misclassified late

This page retains NAFLD/NASH when describing source populations.

Scale and incidence

Approximately one quarter of the global population was estimated to have NAFLD, while NASH incidence was projected to rise with obesity and diabetes (Huang 2021, PMID 33349658).

Population HCC incidence Interpretation
NASH cirrhosis 0.5%–2.6% per year Generally supports cirrhosis surveillance (Huang 2021, PMID 33349658)
Non-cirrhotic NAFLD ~0.1–1.3 per 1,000 patient-years Too low for universal surveillance (Huang 2021, PMID 33349658)
ICD-coded non-cirrhotic NAFLD versus controls Adjusted HR 2.69 (95% CI 1.33–5.44) Relative risk elevated despite low absolute incidence (Lee 2025, PMID 40345323)

The denominators answer different questions. A relative hazard does not establish cost-effective surveillance; annual absolute incidence does not measure the total number of cases in a huge population.

Why HCC can occur without recognized cirrhosis

Possible explanations include:

  • true carcinogenesis in advanced fibrosis short of cirrhosis;
  • metabolic, lipotoxic, oxidative, and inflammatory drivers partially independent of cirrhosis;
  • underdiagnosed or regressed cirrhosis;
  • sampling and coding misclassification;
  • diabetes, age, sex, and genetic susceptibility concentrating risk;
  • a larger liver-at-risk population than in rarer diseases.

A multicentre comparison of MASLD-HCC with and without cirrhosis documents clinically distinct presentation patterns, but observational classification cannot fully exclude occult advanced fibrosis (Vitellius 2024, PMID 39411648).

Risk enrichment

Factor Direction Clinical role Limitation
Advanced fibrosis/cirrhosis Strongest risk enrichment Defines current surveillance core Non-invasive misclassification
Older age Higher risk Simple score component Low specificity
Male sex Higher risk Simple score component Mechanism and equity limits
Type 2 diabetes Higher risk Identifies metabolic severity Common exposure
Obesity Risk and worse ultrasound visualization Prevention and modality planning BMI incompletely captures visceral risk
Ongoing alcohol Adds injury Reclassify mixed etiology Underreported exposure
Platelets/liver stiffness/FIB-4 Fibrosis proxies Scalable enrichment Built for fibrosis, not HCC utility
Germline variants Potential incremental risk Research enrichment Small effects and ancestry transportability

A useful model must find a small enough subgroup to surveil while retaining most future cancers. Discrimination alone is insufficient; calibration, action thresholds, and prospective clinical utility are required.

Surveillance gap

Three failures converge:

  1. Eligibility failure: patients without diagnosed cirrhosis are outside most programmes.
  2. Test failure: obesity and steatotic/nodular parenchyma degrade ultrasound.
  3. Implementation failure: MASLD is often managed in primary care without a cirrhosis registry.

A targeted PubMed search updated 2026-08-30 identified no prospective mortality trial of surveillance in non-cirrhotic MASLD. Current evidence instead consists of risk-stratification and imaging-performance studies, while PREMIUM enrolls cirrhosis rather than this population (Cholankeril 2023, PMID 36216350; NCT05486572).

Strategy Potential Barrier
FIB-4-first case finding Scalable in routine labs Misses some high-risk patients; age dependence
Elastography enrichment Continuous fibrosis signal Access and cutoff variation
Ultrasound visualization score Identifies test failure Requires consistent reporting
Abbreviated MRI Higher sensitivity in selected cohorts Cost/capacity and outcome evidence
AFP/GALAD Operator-independent adjunct False positives and prospective validation
EHR risk registry Repeated dynamic assessment Coding and data-quality bias

Presentation and treatment access

Non-cirrhotic patients may have preserved liver reserve and be candidates for larger resection, but absence from surveillance can produce larger tumors at diagnosis. Cirrhotic MASLD patients may have obesity, diabetes, cardiovascular disease, kidney disease, and frailty that constrain surgery, transplant, anti-VEGF therapy, and immunotherapy.

This produces countervailing effects:

  • better liver function in non-cirrhotic disease;
  • later tumor detection;
  • greater operative opportunity;
  • higher cardiometabolic competing risk;
  • lower transplant candidacy for some patients.

Molecular features

NAFLD-related HCC was associated with TERT promoter mutations and chromosome 8p loss in a genomic study, suggesting recurrent features distinct from some viral tumors (Ki Kim 2016, PMID 27511114). These alterations are not routine treatment selectors.

Candidate mechanistic routes include:

  • lipotoxic hepatocyte injury;
  • oxidative stress and DNA damage;
  • insulin/IGF signaling;
  • altered bile acids and gut-liver signaling;
  • chronic innate inflammation;
  • impaired immune surveillance;
  • fibrosis-dependent matrix and vascular change.

Human tumors remain heterogeneous; no single “MASH-HCC pathway” accounts for every case.

The immunotherapy controversy

Pfister and colleagues combined mouse models, mechanistic work, and trial-level/meta-analytic observations to argue that NASH impairs antitumor immune surveillance and may reduce checkpoint efficacy in nonviral HCC (Pfister 2021, PMID 33762733).

Reasons the signal is biologically important:

  • NASH-specific T-cell states can promote tissue damage without effective tumor control;
  • etiology can shape the immune microenvironment;
  • nonviral subgroups appeared less favorable in some pooled analyses.

Reasons it is not a clinical exclusion rule:

  • subgroup analyses were not powered treatment-by-etiology trials;
  • “nonviral” combines alcohol and metabolic disease;
  • etiology attribution is imperfect and mixed;
  • combination regimens differ from monotherapy models;
  • real-world confounding by liver function and comorbidity is substantial.

The designable test is a prospectively stratified treatment interaction, not another uncontrolled etiologic comparison.

Prevention

Level Intervention HCC-specific evidence boundary
Population Obesity, diabetes, and alcohol prevention Strong risk rationale; HCC endpoint trials impractical
Liver disease Identify and treat MASH fibrosis Fibrosis benefit may translate, but HCC reduction needs long follow-up
Diabetes Optimize cardiometabolic treatment Observational drug associations are confounded
Cirrhosis Six-month HCC surveillance Guideline-supported, ultrasound limitations persist
Post-HCC Control metabolic/alcohol injury Recurrence benefit not isolated from competing effects

Associations of statins, aspirin, metformin, coffee, and incretin therapies with lower HCC risk are hypothesis-generating unless supported by causal designs and HCC-specific endpoints (Singal 2023, PMID 37884736).

Transplant-specific issues

MASLD is an increasing transplant indication, but candidates often carry cardiovascular, renal, and frailty risks. Selection must integrate:

  • coronary and vascular risk;
  • obesity and technical complexity;
  • diabetes control;
  • sarcopenic obesity;
  • recurrence biology;
  • post-transplant metabolic disease.

Metroticket 2.0 and Milan were not designed specifically around MASLD competing mortality, leaving an external-validity question (Mazzaferro 2018, PMID 28989060).

Research design priorities

Question Best next design
Non-cirrhotic surveillance Risk-enriched prospective cohort followed by pragmatic randomized strategy
Ultrasound failure Visualization-triggered MRI comparative-effectiveness trial
Immunotherapy interaction Etiology-stratified randomized pooled individual-patient analysis
Chemoprevention Target-trial emulation followed by pragmatic trial where feasible
Molecular distinction Multi-region tumor plus adjacent-liver spatial profiling

Quantifying a diffuse risk field

MASLD is common—pooled global NAFLD prevalence was 25.24% (95% CI 22.10–28.65)—so population burden can rise even when individual annual HCC incidence outside cirrhosis is low (Younossi 2016, PMID 26707365). Diabetes approximately doubled-to-tripled HCC risk in older pooled epidemiology, but obesity, medication, diet, surveillance, and reverse causation complicate attribution (El-Serag 2006, PMID 16527702). A MASLD-specific meta-analysis of 31 studies and 1.02 million people estimated smoking RR 1.30 (95% CI 1.08–1.57) and also identified alcohol and metabolic control as modifiable correlates (Xiao 2024, PMID 39047929).

Risk dimension Evidence Current use and limitation
Fibrosis/cirrhosis Dominant risk gradient across 29 studies/726,656 NAFLD patients Establishes cirrhosis surveillance; does not solve low absolute risk outside cirrhosis (Guo 2023, PMID 38164853)
Liver stiffness In 30,414 veterans, each 5-kPa increment increased HCC risk by 18% Continuous risk signal; male veteran cohort and retrospective ascertainment limit transportability (John 2026, PMID 40810411)
Non-invasive fibrosis tests IPD/aggregate meta-analysis included 379,194 non-cirrhotic patients Can enrich risk, but no universally accepted cutoff has prospective outcome validation (Siriwong 2025, PMID 39919008)
Diabetes Cohort RR 2.5 (95% CI 1.9–3.2) in cross-etiology meta-analysis Causal contribution likely, but duration, treatment, obesity, and indication bias remain (El-Serag 2006, PMID 16527702)
Mixed etiology Diabetes raised HCC hazard in chronic HBV, random-effects HR 1.36 (95% CI 1.23–1.49) “MASLD-HCC” can coexist with viral carcinogenesis (Campbell 2021, PMID 33305479)
Chemoprevention signals Umbrella review found associations for statins, metformin, aspirin, GLP-1 agents, and bariatric surgery Mostly observational; none is an HCC-prevention indication by itself (Wang 2025, PMID 39834076)

Surveillance has two bottlenecks

The first is eligibility: most non-cirrhotic MASLD patients have risk below conventional surveillance thresholds, while a small subgroup may exceed them. Modeling suggests sequential FIB-4/elastography can be cost-effective for identifying advanced fibrosis, but results depend on test uptake, transition probabilities, costs, and assumed surveillance efficacy (Decharatanachart 2025, PMID 39878449). These are policy models, not trials showing reduced HCC mortality.

The second is test adequacy. In prospective NAFLD-cirrhosis data, severe visualization limitation occurred in 35% with ultrasound versus 19% with abbreviated MRI, and obesity increased odds of ultrasound failure fivefold (Huang 2022, PMID 35229334). A visualization-score-C-triggered MRI strategy was cost-effective in a US model, but MRI price and capacity determine transportability (Mulgaonkar 2024, PMID 38146873). Paired prospective surveillance confirms that non-contrast abbreviated MRI can improve detection in selected high-risk cohorts, not that every MASLD patient should receive MRI (Kim 2024, PMID 38636849).

Metabolic immune biology and the IO controversy

NASH-HCC spatial proteomics classified more than 750,000 cells and found suppressive myeloid populations interacting with exhausted PD-1-positive CD8 T cells, with immune-cell density falling from adjacent liver toward tumor (Li 2024, PMID 37733002). Single-cell/spatial integration across 220 samples identifies POSTN-positive fibroblasts as physical and signaling barriers to T-cell entry, a mechanism not unique to MASLD but relevant to its fibrotic microenvironment (Wang 2024, PMID 39067872).

Pfister and colleagues linked NASH-associated T-cell dysfunction to reduced checkpoint benefit in preclinical models and etiologic subgroup analyses (Pfister 2021, PMID 33762733). This is hypothesis-generating, not a treatment exclusion rule: subgroup analyses are underpowered, etiology classification is noisy, and modern combinations differ from PD-1 monotherapy. Tumor-level immune state may be more predictive than the clinical MASLD label.

Detection biomarkers in MASLD

AFP performs particularly poorly in some metabolic tumors. In a network meta-analysis of 2,031 NAFLD participants, early-stage sensitivity/AUC were 0.34/0.59 for AFP and 0.60/0.74 for DCP; GALAD and DCP performed similarly (Li 2023, PMID 37929312). An international case-control study supported GALAD discrimination in NASH, but only 20% of HCC cases were within Milan criteria and spectrum bias limits surveillance inference (Best 2020, PMID 31712073). Phase-3 cohort validation, not further case-control AUC inflation, is the needed step.

Controversies

  • Non-cirrhotic surveillance. The burden is visible at population level. A 2026-08-30 search found no prospectively validated clinical-utility rule; retrospective liver-stiffness data identify potentially cost-effective strata, but selection and veteran-population transportability remain unresolved (Siriwong 2025, PMID 39919008; John 2026, PMID 40810411).
  • Etiology assignment. Metabolic, alcohol, HBV, and HCV exposures overlap; single-label registries understate interaction and can mislead therapy subgroup analysis (Campbell 2021, PMID 33305479).
  • MRI substitution. Visualization-triggered MRI is more defensible than universal MRI, but cost-effectiveness is health-system specific (Huang 2022, PMID 35229334; Mulgaonkar 2024, PMID 38146873).
  • Checkpoint efficacy. Mechanistic concern is real, yet current clinical evidence is insufficient to deny an active regimen solely because HCC arose in MASLD (Pfister 2021, PMID 33762733; Li 2024, PMID 37733002).

Open questions

  • What absolute-risk threshold and model can select non-cirrhotic MASLD for surveillance (Huang 2021, PMID 33349658)?
  • Does MASLD etiology predict less benefit from specific checkpoint regimens after proper interaction testing (Pfister 2021, PMID 33762733)?
  • Can fibrosis regression lower risk enough to stop surveillance?
  • Which metabolic therapy reduces HCC incidence independently of weight, diabetes, and fibrosis confounding?
  • Do transplant prediction models require recalibration for MASLD competing cardiovascular mortality?

References

  1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223-238. PMID 33349658
  2. Lee CH, et al. HCC risk in ICD-coded non-cirrhotic NAFLD refined by fatty liver index: a nationwide South Korean cohort. Clin Res Hepatol Gastroenterol. 2025;49:102612. PMID 40345323
  3. Vitellius C, et al. MASLD-related HCC: multicenter study comparing patients with and without cirrhosis. JHEP Rep. 2024. PMID 39411648
  4. Cholankeril G, et al. Current challenges and future direction in surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2023;43:89-99. PMID 36216350
  5. Ki Kim S, et al. TERT promoter mutations and chromosome 8p loss are characteristic of NAFLD-related HCC. Int J Cancer. 2016;139:2512-2518. PMID 27511114
  6. Pfister D, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450-456. PMID 33762733
  7. Singal AG, Kanwal F, Llovet JM. Global trends in HCC epidemiology. Nat Rev Clin Oncol. 2023;20:864-884. PMID 37884736
  8. Mazzaferro V, et al. Metroticket 2.0 model for analysis of competing risks after liver transplantation for HCC. Gastroenterology. 2018;154:128-139. PMID 28989060
  9. Guo WP, et al. Risk factors of HCC in NAFLD: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2023;27:11890-11903. PMID 38164853
  10. Xiao S, et al. Modifiable risk factors for HCC in MASLD: a meta-analysis. Am J Med. 2024;137:1072-1081.e32. PMID 39047929
  11. Wang J, et al. Risk factors for HCC: an umbrella review. Ann Med. 2025;57:2455539. PMID 39834076
  12. El-Serag HB, et al. The association between diabetes and HCC: a systematic review. Clin Gastroenterol Hepatol. 2006;4:369-380. PMID 16527702
  13. Mulgaonkar A, et al. Cost-effectiveness of visualization-triggered abbreviated MRI in NAFLD cirrhosis. Am J Gastroenterol. 2024;119:1326-1336. PMID 38146873
  14. Decharatanachart P, et al. Cost-utility of noninvasive tests to initiate HCC surveillance in MASLD. Am J Gastroenterol. 2025;120:2592-2602. PMID 39878449
  15. John BV, et al. Liver stiffness for HCC risk stratification in MASLD. Hepatology. 2026;83:1456-1468. PMID 40810411
  16. Siriwong N, et al. Noninvasive tests for HCC prediction in non-cirrhotic NAFLD: IPD meta-analysis. Eur J Gastroenterol Hepatol. 2025;37:358-369. PMID 39919008
  17. Huang DQ, et al. Ultrasound versus abbreviated MRI in NAFLD cirrhosis. Aliment Pharmacol Ther. 2022;55:820-827. PMID 35229334
  18. Kim DH, et al. Non-contrast abbreviated MRI versus ultrasound for HCC surveillance. J Hepatol. 2024;81:461-470. PMID 38636849
  19. Li M, et al. Spatial proteomics of the immune microenvironment in NASH-associated HCC. Hepatology. 2024;79:560-574. PMID 37733002
  20. Wang H, et al. POSTN-positive fibroblasts determine immunotherapy efficacy in HCC. J Immunother Cancer. 2024;12. PMID 39067872
  21. Li H, et al. GALAD and serum biomarkers for detecting NAFLD-related HCC: network meta-analysis. Expert Rev Gastroenterol Hepatol. 2023;17:1159-1167. PMID 37929312
  22. Best J, et al. GALAD detects early HCC in an international NASH cohort. Clin Gastroenterol Hepatol. 2020;18:728-735.e4. PMID 31712073
  23. Campbell C, et al. Metabolic risk factors for HCC in chronic HBV: a meta-analysis. J Viral Hepat. 2021;28:493-507. PMID 33305479
  24. Younossi ZM, et al. Global epidemiology of NAFLD: meta-analytic assessment. Hepatology. 2016;64:73-84. PMID 26707365
  25. Fan R, et al. aMAP risk score predicts HCC development in chronic hepatitis. J Hepatol. 2020;73:1368-1378. PMID 32707225